AU2019286795B2 - IL-11 antibodies - Google Patents

IL-11 antibodies

Info

Publication number
AU2019286795B2
AU2019286795B2 AU2019286795A AU2019286795A AU2019286795B2 AU 2019286795 B2 AU2019286795 B2 AU 2019286795B2 AU 2019286795 A AU2019286795 A AU 2019286795A AU 2019286795 A AU2019286795 A AU 2019286795A AU 2019286795 B2 AU2019286795 B2 AU 2019286795B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
antigen
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019286795A
Other languages
English (en)
Other versions
AU2019286795A1 (en
Inventor
Stuart Alexander COOK
Sebastian Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
National University of Singapore
Singapore Health Services Pte Ltd
Original Assignee
Boehringer Ingelheim International GmbH
National University of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, National University of Singapore, Singapore Health Services Pte Ltd filed Critical Boehringer Ingelheim International GmbH
Publication of AU2019286795A1 publication Critical patent/AU2019286795A1/en
Priority to AU2026201704A priority Critical patent/AU2026201704A1/en
Application granted granted Critical
Publication of AU2019286795B2 publication Critical patent/AU2019286795B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
AU2019286795A 2018-06-13 2019-06-13 IL-11 antibodies Active AU2019286795B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201704A AU2026201704A1 (en) 2018-06-13 2026-03-05 IL-11 antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1809699.0 2018-06-13
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
PCT/EP2019/065598 WO2019238882A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201704A Division AU2026201704A1 (en) 2018-06-13 2026-03-05 IL-11 antibodies

Publications (2)

Publication Number Publication Date
AU2019286795A1 AU2019286795A1 (en) 2021-01-28
AU2019286795B2 true AU2019286795B2 (en) 2026-03-12

Family

ID=63042160

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019286795A Active AU2019286795B2 (en) 2018-06-13 2019-06-13 IL-11 antibodies
AU2026201704A Pending AU2026201704A1 (en) 2018-06-13 2026-03-05 IL-11 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201704A Pending AU2026201704A1 (en) 2018-06-13 2026-03-05 IL-11 antibodies

Country Status (25)

Country Link
US (4) US11084874B2 (enExample)
EP (1) EP3807314A1 (enExample)
JP (2) JP2021535733A (enExample)
KR (1) KR20210031690A (enExample)
CN (1) CN113056481A (enExample)
AU (2) AU2019286795B2 (enExample)
BR (1) BR112020025443A2 (enExample)
CA (1) CA3102483A1 (enExample)
CL (1) CL2020003223A1 (enExample)
CO (1) CO2020015383A2 (enExample)
CR (1) CR20210009A (enExample)
DO (2) DOP2020000245A (enExample)
EA (1) EA202092668A1 (enExample)
EC (1) ECSP21000695A (enExample)
GB (1) GB201809699D0 (enExample)
IL (1) IL279356A (enExample)
JO (1) JOP20200309A1 (enExample)
MA (1) MA52884A (enExample)
MX (2) MX2020013583A (enExample)
PE (1) PE20211498A1 (enExample)
PH (1) PH12020552232A1 (enExample)
SA (1) SA520420801B1 (enExample)
SG (1) SG11202011782XA (enExample)
TW (1) TWI924625B (enExample)
WO (1) WO2019238882A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4181959A4 (en) * 2020-07-20 2024-11-06 Razi Holdings, Inc. Broadly neutralizing binding molecules against marburgviruses
JP2023537422A (ja) * 2020-08-13 2023-08-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｉｌ－１１の抗体及びその使用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CA3211686A1 (en) * 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN115975027B (zh) * 2021-08-12 2023-10-20 广东东阳光药业股份有限公司 Il-11人源化抗体及其应用
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
EP4471060A4 (en) * 2022-01-29 2025-08-27 Mabwell Shanghai Bioscience Co Ltd ANTI-INTERLEUKIN-11 ANTIBODY AND ITS USE
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024146458A1 (zh) 2023-01-06 2024-07-11 广东东阳光药业股份有限公司 抗il-11细胞因子人源化抗体
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518762B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
IL326237A (en) * 2023-07-28 2026-03-01 Mabwell Shanghai Bioscience Co Ltd Use of anti-interleukin-11 antibody in the preparation of a drug for the treatment of tumors
CN122270478A (zh) * 2023-11-22 2026-06-23 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白
CN122497697A (zh) 2024-01-02 2026-07-31 上海华奥泰生物药业股份有限公司 靶向il-11和tslp的多特异性分子
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026001793A1 (zh) * 2024-06-27 2026-01-02 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白及其用途
CN119119262B (zh) * 2024-08-02 2025-05-02 杭州曼迪生物科技有限公司 一种干细胞冻干粉及其在制备药物或者化妆品中的用途
WO2026125705A2 (en) * 2024-12-12 2026-06-18 Lead Discovery Center Gmbh Inhibitory antibodies of cytokine interleukin 11 dependent signaling pathways
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103108A1 (en) * 2015-12-16 2017-06-22 Singapore Health Services Pte Ltd Treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103108A1 (en) * 2015-12-16 2017-06-22 Singapore Health Services Pte Ltd Treatment of fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG M ET AL: "Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, *

Also Published As

Publication number Publication date
IL279356A (en) 2021-01-31
SA520420801B1 (ar) 2023-12-07
MA52884A (fr) 2021-04-21
TWI924625B (zh) 2026-05-11
JOP20200309A1 (ar) 2020-11-30
JP2021535733A (ja) 2021-12-23
CO2020015383A2 (es) 2021-04-19
CR20210009A (es) 2021-06-21
PH12020552232A1 (en) 2021-06-28
TW202003560A (zh) 2020-01-16
US20240270837A1 (en) 2024-08-15
MX2020013583A (es) 2021-04-13
SG11202011782XA (en) 2020-12-30
US20200031918A1 (en) 2020-01-30
WO2019238882A1 (en) 2019-12-19
GB201809699D0 (en) 2018-08-01
CN113056481A (zh) 2021-06-29
CL2020003223A1 (es) 2021-07-30
US20240190953A1 (en) 2024-06-13
KR20210031690A (ko) 2021-03-22
ECSP21000695A (es) 2021-03-31
DOP2024000220A (es) 2025-02-28
MX2026004613A (es) 2026-06-01
EA202092668A1 (ru) 2021-05-18
AU2019286795A1 (en) 2021-01-28
US11084874B2 (en) 2021-08-10
CA3102483A1 (en) 2019-12-19
AU2026201704A1 (en) 2026-03-26
BR112020025443A2 (pt) 2021-03-16
DOP2020000245A (es) 2021-10-31
JP2024105466A (ja) 2024-08-06
PE20211498A1 (es) 2021-08-11
EP3807314A1 (en) 2021-04-21
US20210230266A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US20240190953A1 (en) Il-11 antibodies
US11084878B2 (en) IL-11Rα antibodies
US11078268B2 (en) IL-11 antibodies
US11078269B2 (en) IL-11Rα antibodies
TW201833135A (zh) 抗－ＴＧＦ－β抗體及其用途
WO2024008960A1 (en) Cnx antigen-binding molecules
EA048010B1 (ru) Антитела к ил-11

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)